Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer

Oncology Reports

Volumn 9, Issue 3, 2002, Pages 661-670

  Mantovani, Giovanni ^a   MacCiò, Antonio ^c   Mulas, Carlo ^a   Massa, Elena ^a   Madeddu, Clelia ^a   Mura, Loredana ^a   Contu, Paolo ^a   Versace, Renato ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Ematologia CTMO   (Italy)

^c Sirai Hospital   (Italy)

Author keywords

Chemotherapy; Clinical response; Interleukin 2; Medroxyprogesterone acetate; Non small cell lung cancer stage IIIB IV; Phase II study

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-2; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; QUALITY OF LIFE; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036583341     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.3.661     Document Type: Article

References (44)

1. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327: 1434-1441, 1992.
2. Grilli R, Oxman AD and Julian JA: Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 11: 1866-1872, 1993. (Pubitemid 23304609)
3. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342: 19-21, 1993. (Pubitemid 23183916)
4. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899-909, 1995.
5. Donnadieu N, Paesmans M and Sculier JP: Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer 7: 243-252, 1991.
6. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626, 1991.
7. Bruera E: Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 49 (Suppl 2): 35-52, 1992.
8. Brennan BR: Uncomplicated starvation vs. cancer cachexia. Cancer Res 37: 2359-2364, 1997.
9. Mantovani G, Macciò A, Bianchi A, et al: Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 25: 135-141, 1995.
10. Mantovani G, Macciò A, Esu S, et al: Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 33: 602-607, 1997. (Pubitemid 27223745)
11. Mantovani G, Macciò A, Lai P, et al: Medroxyprogesterone acetate and megestrol acetate reduce cisplatin-induced serotonin release from human peripheral blood mononuclear cells (PBMC) of cancer patients. Oncol Rep 5: 121-124, 1998.
12. Mantovani G, Macciò A, Lai P, et al: Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 25 (Suppl 6): 45-52, 1998. (Pubitemid 28268504)
13. Mantovani G, Macciò A, Lai P, et al: Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 9: 99-106, 1998. (Pubitemid 29079042)
14. Mantovani G, Macciò A, Lai P, et al: Results of a dose-intense phase I study of a combination chemotherapy regimen with cisplatin (CDDP) and epidoxorubicin (EPI) including medroxyprogesterone acetate (MPA) and recombinant interleukin 2 (rIL-2) in patients with inoperable primary lung cancer. J Immunother 23: 267-274, 2000. (Pubitemid 30165176)
15. Feld R, Wierzbicki R, Walde PLD, et al: Phase I-II study of high-dose epirubicin in advanced non-small cell lung cancer. J Clin Oncol 10: 297-303, 1992.
16. Wils J, Utama I, Sala L, et al: Phase II study of high-dose epirubicin in non-small cell lung cancer. Eur J Cancer 26: 1140-1141, 1990.
17. Martoni A, Melotti B, Guaraldi M, et al: Activity of high-dose epirubicin in advanced non-small cell lung cancer. Eur J Cancer 27: 1231-1234, 1991.
18. Smit EF, Berendsen HM, Piers DA, et al: A phase II study of high-dose epirubicin in unresectable non-small cell lung cancer. Br J Cancer 65: 405-408, 1992.
19. Villar A, Anton E, Jimeno J, et al: Fractionated high dose (HD) of epirubicin (E) in adenocarcinoma of the lung (ADL). Lung Cancer 7 (Suppl): 451, 1991.
20. Martoni A, Guaraldi M, Casadio M, et al: A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small cell lung cancer (NSCLC). Ann Oncol 3: 864-866, 1992. (Pubitemid 23002482)
21. Clerici M, De Marinis F, Piazza E, et al: Phase II study of the activity and tolerability combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer. Tumori 84: 669-672, 1998. (Pubitemid 29086524)
22. Martoni A, Guaraldi M, Piana E, et al: Multicenter randomized clinical trial on high-dose epirubicin plus cisplatin versus vinorelbine plus cisplatin in advanced non-small cell lung cancer. Lung Cancer 22: 31-38, 1998. (Pubitemid 28526441)
23. Ardizzoni A, Bonavia M, Viale M, et al: Biological and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer. Cancer 73: 1353-1360, 1994. (Pubitemid 24072539)
24. Schiller JH, Morgan-Ihrig C and Levitt ML: Concomitant administration of IL-2 plus TNF-alpha in advanced non-small cell lung cancer. Br J Cancer 73: 1560-1562, 1994.
25. Tester WJ, Kim KM, Krigel RL, et al: A randomized phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study. Lung Cancer 25: 199-206, 1999. (Pubitemid 29421627)
26. Lissoni P, Meregalli S, Fossati V, et al: A randomized study of immunotherapy with low-dose s.c. IL-2 plus melatonin vs. chemotherapy with CDDP and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 80: 464-467, 1994.
27. Packer L, Witt EH and Tritschler HJ: Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 19: 227-250, 1995.
28. Han D, Handelman G, Marcocci L, et al: Lipoic acid increases de novo synthesis of cellular glutathione by improving cysteine utilization. Biofactors 6: 321-338, 1997. (Pubitemid 27487808)
29. Behr J, Maier K, Degenkolb B, et al: Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 156: 1897-1901, 1997. (Pubitemid 28011799)
30. Mantovani G, Macciò A, Melis G, et al: Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int J Cancer 86: 842-847, 2000. (Pubitemid 30350200)
31. WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication no. 48, Geneva, 1979.
32. Miller AB, Hodgstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981. (Pubitemid 11167383)
33. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
34. Tamburini M, Rosso S, Gamba A, et al: A therapy impact questionnaire for quality-of-life assessment in advanced cancer research. Ann Oncol 3: 565-570, 1992.
35. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1959.
36. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994.
37. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group Study. J Clin Oncol 16: 2459-2465, 1998. (Pubitemid 28309041)
38. Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18: 122-130, 2000. (Pubitemid 30036345)
39. Cardenal F, Lopez-Caperizo MP, Antòn A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17: 12-18, 1999. (Pubitemid 29022372)
40. Crinò L, Scagliotti GV, Ricci S, et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian lung cancer project. J Clin Oncol 17: 3522-3530, 1999. (Pubitemid 29517923)
41. Gatzemeier U, Rosell R, Betticher D, et al: Randomized Pan-European trial comparing paclitaxel (TAX)/carboplatin(CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC). Eur J Cancer 35 (Suppl 4): S246, 1999.
42. Nomura Y, Tashiro H, Shirouzu M, et al: Chemo-endocrine therapy including mytomicin C and medroxyprogesterone acetate in doxorubicin-refractory advanced breast cancer. Gan To Kagaku Ryoho 23: 439-445, 1996. (Pubitemid 26119990)
43. Tashiro H and Nomura Y: Mitomycin C, metothrexate, and vincristine with medroxyprogesterone acetate or prednisolone for doxorubicin resistant breast cancer: a randomized controlled study. Anticancer Res 15: 2229-2237, 1995. (Pubitemid 26031305)
44. Mantovani G, Bianchi A, Curreli L, et al: Neo-adjuvant chemotherapy ± immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck. A pilot study. Biotherapy 8:91-98, 1995.